Ò
-derived anti-interleukin (IL)-4Ra mAb that inhibits signaling of IL-4/IL-13, key drivers of type 2 inflammation, is approved for treatment of adults with inadequately controlled moderate-to-severe atopic dermatitis. This analysis of the phase 3 LIBERTY ASTHMA QUEST study (NCT02414854) in uncontrolled, moderate-to-severe asthma patients assessed dupilumab's effect on the Standardized Rhinoconjunctivitis Quality of Life Questionnaire [RQLQ(S)+12] in patients with self-reported comorbid AR. METHODS: Asthma patients, > _12 years, uncontrolled with medium-tohigh-dose ICS plus < _2 additional controllers received add-on dupilumab 200/300mg or matched placebo every 2 weeks (q2w) (20.44[20.68,20.21]/20.39 [20.61,20.16] ), sleep (20.47[20.69,20.25]/20.38[20.59,20 .17]), and eye symptoms (20.37[20.58,20.16]/20.39[20.59,20.19] ) domain scores from baseline to Week 52 vs placebo; and by Week 12 for dupilumab 300mg (20.23[20.42,20.04], 20.26[20.45,20.07], 20.26[20.45, 20 .08] respectively; P<0.05). Nasal symptoms domain scores significantly improved with dupilumab 200/300mg vs placebo by Week 12 (20.36 [20.56, 20.16]/20.32[20.51, 20 .13];P<0.001) and Week 52 (20.61 [20.84,20.39]/20.55[20.76,20 .33];P<0.0001). The most common adverse event, with higher frequency in dupilumab vs placebo, was injection-site reactions (15%/18%vs5%/10%). CONCLUSIONS: Dupilumab significantly improved rhinoconjunctivitis-specific health-related quality of life in patients with uncontrolled, moderate-to-severe asthma and comorbid AR, and was generally well tolerated. annualised rate of clinically significant exacerbations & exacerbations requiring hospitalization/ED visit, and patients with no clinically significant exacerbations; these were assessed by baseline blood eosinophil count category (<150 [historical] , 150-<300, 300-<500, > _500 cells/mL) & threshold (> _150, > _300, > _400 cells/mL) using negative binomial or logistic regression. RESULTS: 936 patients were included (468 mepolizumab; 468 placebo). 
